DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2hpk77/metastatic_uveal) has announced the addition of the "Metastatic Uveal Melanoma - Pipeline Review, H2 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Metastatic Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Uveal Melanoma and special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Companies Involved in Therapeutics Development
- AstraZeneca PLC
- Eli Lilly and Company
- GlaxoSmithKline plc
- Novartis AG
- Spectrum Pharmaceuticals, Inc.
- selumetinib sulfate
- vincristine sulfate
- trametinib dimethyl sulfoxide + uprosertib
- sotrastaurin acetate
For more information visit http://www.researchandmarkets.com/research/2hpk77/metastatic_uveal